Yifeng Pharmacy Chain (603939) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached RMB 6.01 billion, up 0.64% year-over-year.

• Net profit attributable to shareholders was RMB 449.49 million, a 10.51% increase year-over-year.

• Net increase of 10 stores in Q1, with 94 new stores opened and 84 closed; total store count at 14,694.

Financial highlights

• Operating cash flow surged 71.42% year-over-year to RMB 1.11 billion, driven by faster receivables collection.

• Basic EPS was RMB 0.37, up 12.12% year-over-year; diluted EPS was RMB 0.36, up 9.09%.

• Gross profit for Q1 was RMB 617.96 million, with operating profit at RMB 650.54 million.

• Total assets at quarter-end were RMB 27.79 billion, down 0.67% from year-end 2024.

• Shareholders’ equity attributable to the parent was RMB 11.19 billion, up 4.28% from year-end.

Key financial ratios and metrics

• Weighted average ROE was 4.02%, slightly down from 4.06% a year ago.

• Net margin improved, with net profit growth outpacing revenue growth.